Ballentine Partners Portfolio holdings
Top Buys
| 1 |
Vanguard Total Stock Market ETF
VTI
|
+$13.2M |
| 2 |
iShares MSCI EAFE Small-Cap ETF
SCZ
|
+$11.2M |
| 3 |
PepsiCo
PEP
|
+$4.53M |
| 4 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$4.5M |
| 5 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$2.29M |
Top Sells
| 1 |
iShares Russell 1000 ETF
IWB
|
+$1.29M |
| 2 |
iShares Core S&P Small-Cap ETF
IJR
|
+$1.11M |
| 3 |
Pfizer
PFE
|
+$1.07M |
| 4 |
Accenture
ACN
|
+$592K |
| 5 |
AGN
Allergan plc
AGN
|
+$408K |
Sector Composition
| 1 | Industrials | 1.79% |
| 2 | Financials | 1.43% |
| 3 | Technology | 1.39% |
| 4 | Healthcare | 1.13% |
| 5 | Consumer Discretionary | 1.03% |
Similar funds
Ballentine Partners's Q4 2016 Portfolio in Review
As of Q4 2016, Ballentine Partners held 232 positions worth $1.29B, up 5.1% from $1.23B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Ballentine Partners deployed $45.8M of net new capital in Q4 2016, opening 24 new positions and adding to 85 existing holdings. Its largest new stake was PIMCO Enhanced Short Maturity Active Exchange-Traded Fund: 12,424 shares worth $1.25M.
By sector, the portfolio is most concentrated in Industrials at 1.8% of assets, down from 1.8% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was iShares Russell 1000 ETF, an estimated $1.29M trimmed.
- Ballentine Partners's largest Q4 2016 buy was PIMCO Enhanced Short Maturity Active Exchange-Traded Fund: 12,424 shares worth $1.25M.
- Ballentine Partners added most to Vanguard Total Stock Market ETF in Q4 2016, an estimated $13.2M increase.
- Ballentine Partners's biggest Q4 2016 reduction was iShares Russell 1000 ETF, cutting an estimated $1.29M.
- Ballentine Partners fully exited Accenture in Q4 2016, selling an estimated $592K.
- Ballentine Partners's ten largest holdings make up 71% of its $1.29B portfolio in Q4 2016.
- Ballentine Partners opened 24 new positions and closed 32 in Q4 2016.
- Ballentine Partners's portfolio value rose 5.1% quarter-over-quarter to $1.29B.
Based on Ballentine Partners's 13F filing for Q4 2016, filed 3 Feb 2017.